How Ro uses a news-headline greenscreen to launch a GLP-1 pill | Fluid
Esc

How Ro uses a news-headline greenscreen to launch a GLP-1 pill

A 46-second greenscreen video. A creator, disclosed as sponsored by Ro and not a Ro member or GLP-1 patient, stands in front of a Medical News Today headline about the FDA approving the Foundayo pill. She explains what it is, who makes it and how it's taken, then says it's available on Ro. The click lands on Ro's quiz.

Ro
71 creatives lead here1 / 71
Ro · Serena-led weight-loss quiz

Public page captured October 22, 2026. Promotional sheets and temporary interface overlays were dismissed or removed in the static reference. No personal or medical information was entered. Captured entry screens do not reproduce the complete consultation.

Ro: full page screenshot

See if you qualify

Visual reference: News headline · creator commentary. The main campaign sends price, medication-launch, creator and celebrity ads to one Serena-led entrance. A treatment-format question sits in the hero; choosing Learn about both reveals a weight-goal question without leaving the page. Compare the creative with the destination and explore the other ads sharing this route.

Brand
Ro
Observed offer
Online GLP-1 assessment; medication and membership terms apply
Creative angle
Education
Page type
Quiz entry
Ad format
Video · 0:46
Listed start date
Sep 1, 2026
Captured
Oct 22, 2026
Library ID
28291866770454304
Destination
ro.co

Selected for its design and offer structure. Ad performance isn’t available in this collection.

What this ad does well

The greenscreen over a real news headline borrows the feel of breaking news, which suits a launch: the viewer sees an approval story first and the brand second. The creator talks like a friend explaining something she read, covering who makes the pill, that it can be taken any time daily, and who it's for, with the line "if you're not into shots" naming a real objection in plain words. The disclosure sits right on screen ("Not a Ro member or GLP-1 patient"), which keeps the format transparent.

What's missing

Because the creator is disclosed as neither a member nor a patient, there's no personal proof, so the ad is news commentary with a link at the end. The affordability claim near the close has no price attached, which leaves the most practical question unanswered after a long build-up. At 46 seconds, the payoff also arrives late. If you use this format, bring the price or offer forward and pair the commentary with a clip from a real customer.

Beat by beat

  1. 0-5s
    A creator stands over a news headline about the FDA approving the Foundayo pill, with a caption calling it the newest FDA-approved GLP-1 pill and an on-screen sponsorship disclosure.

    It opens on news, which feels like information rather than an ad.

  2. 5-20s
    She says the pill is available on Ro and comes from the makers of Zepbound, as product shots of the bottle appear.

    It ties the new name to a brand the viewer may already know.

  3. 20-35s
    She explains it can be taken any time daily and suggests it for people who aren't into shots.

    It speaks to people put off by injections.

  4. 35-46s
    She claims these pills are the most affordable cash-pay options and tells viewers to see if they qualify at ro.co.

    It closes on price and the next step.

The offer

No price is stated. The creator claims FDA-approved GLP-1 pills are the most affordable cash-pay options and invites viewers to see if they qualify.

Where it sends people

The ad sends people to Ro's weight-loss quiz entry, the destination for 71 of the 100 Ro ads in the Fluid library. A quiz sits on the strongest rung of the landing-page ladder, and this one starts fast: the page opens on "Lose weight on Ro," a banner claiming "The lowest prices for GLP-1s are on Ro," a photo of Serena Williams labeled as a Ro member, and a card asking "Which Ro option are you interested in?" with GLP-1 pill, GLP-1 shot, both, or a provider recommendation as the answers. The pill answer matches the ad, but the page doesn't name Foundayo, so a viewer who clicked for the newest pill can't confirm it's the one on offer until later. Naming the new pill near the question card, or linking this ad to a pill-specific entry, would make the news-to-page handoff tighter.

The page it sends people to: How Ro turns its Serena Williams ads into a one-question start

Ro's main weight-loss landing page is a quiz entry: Serena Williams, labeled as a Ro member, stands beside a card asking which GLP-1 option you want. It's the destination for 71 Ro ads in the Fluid library, mostly price-led statics, Serena creator videos and pill-versus-pen product stills, nearly all ending on See if you qualify.

How the page is built

  1. 01
    Announcement bar

    A pale yellow strip claims the lowest prices for GLP-1s are on Ro, the page's only answer to 'is this affordable?'

  2. 02
    Headline

    Lose weight on Ro names the category and the brand, so the visitor knows they're in the right place before reading anything else.

  3. 03
    Serena Williams photo

    Serena holds a pen-style product with a Ro member label and a product thumbnail beside her, answering 'is this the thing from the ad?'

  4. 04
    Treatment-format question

    A white card asks which Ro option you're interested in (pill, shot, learn about both, or a provider recommendation), which starts the quiz and sorts visitors by how far along they are.

  5. 05
    Weight-goal question

    After Learn about both, the same card asks how much weight you're looking to lose in ranges plus Not sure yet, keeping the visitor on the page while the quiz continues.

  6. 06
    Footer

    Legal, terms, privacy and consumer health data privacy links sit beside a LegitScript Certified badge, answering 'is this a legitimate pharmacy?' for anyone who scrolls.

The first fixes we would make

  1. Many of the ads sending traffic here lead with price (Half the price, Affordable GLP-1, Same results, more savings), and the page answers with one general claim in the announcement bar. Put a starting price under each format option, using the same number the ad showed, so the person who clicked for the price sees it before they answer.
  2. The format question asks people to choose between a pill and a shot with nothing beside either option. Add a short line under each choice that describes it the way the product-choice ads already do, so someone arriving from a Pill or pen ad can pick without leaving to research.

Read the full breakdown of this page

Three hooks you could test

  • Lead with the uncomfortable problem. “Not into needles? Here's the news you might have missed.”
  • Show a specific moment of use. “Take it whenever your day allows, like any other daily pill.”
  • Turn the benefit into a picture people get in a second. “The headline everyone's sharing, explained in thirty seconds.”

What to borrow for your brand

  • Stand a creator in front of a real headline about your category so the ad opens as news, then explain it in plain language.
  • Put any sponsorship or not-a-customer disclosure on screen early so the format stays honest.
  • Name the objection your new format solves (no shots, no prep, no mess) in the creator's own casual words.

Transcript

The new GLP one pill foundeo dropped and it's available on rogue. Foundeo is the newest FDA approved GLP one pill you might be hearing about, and it's from the makers of Zebound. You could take it anytime daily, just like other common pills, so it's super flexible. So if you're not into shots. This once daily pill could be a great option. Now these FDA approved GLP1 pills are the most affordable cash pay options around, which is such a game changer. See if you qualify it, row.co.
Text on screen
  • MEDICALNEWSTODAY
  • SUBSCRIBE
  • FDA approves Wegovy-
  • like GLP-1 pill,
  • Foundayo, for weight
  • loss
  • Written by
  • The NEWEST
  • Fact chec
  • FDA-approved GLP-1 pill
  • for weight loss is here
  • Sponsored by Ro: Not a Ro member or CLPa patient
  • PROT
  • 000000-6176-41
  • Foundayo
  • OTE
  • TECTED
  • TED
  • The new GLP-1 pili, Foundayo demand for
  • edical News Today/Photo
  • Administration (FDA) has
  • gon-like peptide-1 (GLP.
  • hich offers a
  • or weiaht
  • Sponsored by Ro. Not a Ro member or GLPa patient
  • ROY
  • HOC 0012-4178-05
  • STECTED
  • CED
  • The new GLP-1 pill, Foundayo demand for
  • Medical News Today/Photo
  • Foundayo (orforglipron), a
  • agon-like peptide-1 (GLP.
  • which offers a
  • for weiaht
  • Sponsored by Ro. Not a Ro memberior GUPa patient
  • ROS
  • NOC 0018-4178-61
  • Foundaya
  • OTECTED,

One of 100 Ro ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.